← Back to Clinical Trials
Recruiting NCT06754709

NCT06754709 Evaluation of Blood and Cardiac Protein O-GlcNAcylation Levels in Cardiac Surgery in Children

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06754709
Status Recruiting
Phase
Sponsor Nantes University Hospital
Condition Cardiac Surgery
Study Type OBSERVATIONAL
Enrollment 300 participants
Start Date 2025-02-13
Primary Completion 2034-01-31

Trial Parameters

Condition Cardiac Surgery
Sponsor Nantes University Hospital
Study Type OBSERVATIONAL
Phase N/A
Enrollment 300
Sex ALL
Min Age N/A
Max Age 17 Years
Start Date 2025-02-13
Completion 2034-01-31

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

Cardiac surgery requires the use of extracorporeal circulation (ECC). Age-related differences in inflammatory response, the greater susceptibility of immature organ systems to injury and the larger ratio of extracorporeal circuitry to patient size make younger and smaller patients more vulnerable to organ injury. The main problem associated with ECC in neonates and infants is the duration of ECC due to heavier surgeries leading to a prolonged inflammatory state resulting in capillary leak syndrome, low cardiac output syndrome and organ dysfunction, resulting in higher morbidity and mortality. The means of limiting this inflammatory response remain limited. Future studies should aim to address new post-ECC prophylactic targets to improve myocardial and endothelial function. Cardiac metabolism is an important area of research because it plays a central role in maintaining cardiac function under stress. The study of O-GlcNAcylation could therefore be an interesting therapeutic target, given the beneficial role of its stimulation in acute stress situations, as demonstrated in sepsis.

Eligibility Criteria

Inclusion Criteria: * Age from 0 to 17 years at the time of sampling * Children undergoing CEC for cardiac surgery * Signed bio-collection consent Exclusion Criteria: * Children with an infection * Children with fever * Children with an immune deficiency * Children with autoimmune disease * Children with metabolic disease * Children with haematological diseases * Children with a genetic disease * Unsigned consent * Refusal by parents or child

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology